GHRP-2 (Pralmorelin) is a synthetic growth hormone secretagogue that triggers strong GH release but also raises cortisol and prolactin — making it more potent than ipamorelin and harder to use cleanly.
What it does
GHRP-2 is a synthetic hexapeptide (a chain of six amino acids) that binds the GHS-R1a receptor — the same receptor activated by ghrelin, the body's natural hunger-and-GH signal. Binding that receptor on pituitary somatotrophs (the cells that make and release growth hormone) triggers a calcium-dependent signaling cascade that forces those cells to release GH in a pulse. At the same time, GHRP-2 suppresses somatostatin, the hormone that normally puts the brakes on GH secretion, effectively hitting the accelerator and cutting the brakes simultaneously Sawako 2022 Takanori 2024.
Where GHRP-2 diverges from cleaner GH secretagogues like ipamorelin is what else it does. At any dose large enough to release meaningful GH, GHRP-2 also stimulates the ACTH pathway — ACTH (adrenocorticotropic hormone) is the pituitary signal that tells the adrenal glands to release cortisol. The result is a measurable cortisol spike alongside the GH pulse Tomohide 2025 Kazuki 2021. Prolactin also rises. These off-target effects are not incidental — they are baked into the receptor pharmacology and cannot be dialed out with lower doses without sacrificing GH output.
GHRP-2 also activates ghrelin receptors in the gut and hypothalamus, which produces a moderate increase in appetite — more pronounced than ipamorelin but less extreme than GHRP-6. For users trying to increase caloric intake alongside GH, this can be useful. For those who are not, it is an additional variable to manage.
What the evidence shows
GH deficiency testing and diagnosis Solid human clinical data — used as a validated diagnostic tool in Japan and studied across age groups
The GHRP-2 stimulation test — measuring the GH response to a single injected dose — is a well-established clinical tool for diagnosing GH deficiency. Multiple Japanese endocrinology studies have validated its use across different populations, including adolescents Takanori 2024 and elderly patients Shinichiro 2023. The test reliably distinguishes pituitary GH reserve from hypothalamic dysfunction, with known cutoffs for what counts as an adequate response Sawako 2022. This is the most evidence-backed application of GHRP-2 — it is not experimental here; it is diagnostic medicine Kazuki 2021 Kumiko 2021.
Tendon and soft tissue repair Early rodent data only — no human trials
One 2025 rat rotator cuff model found that GHRP-2 treatment was associated with reduced M1 macrophage activity (M1 macrophages drive acute inflammation) and improved histological and biomechanical markers of tendon-to-bone healing Yinghao 2025. The mechanism likely involves GH-driven anabolic signaling and immune modulation. This is interesting preliminary data, but it is a single rodent study. Human evidence does not yet exist for this use case.
Cachexia and wasting conditions Theoretical and review-level; limited direct trial data
GHRP-2 has been discussed in the context of cachexia (severe muscle and weight loss associated with chronic illness or cancer) because GH secretagogues can increase lean mass and appetite. One review of pharmacotherapy in cachexia included GH secretagogues among candidate agents for managing endocrine abnormalities in wasting Magdalena 2022. No large controlled trials of GHRP-2 specifically for cachexia have been published. The appetite-stimulating and anabolic properties are biologically plausible, but clinical evidence remains thin.
Pituitary and adrenal axis assessment Human case and cohort data — primarily diagnostic
Because GHRP-2 stimulates both GH and ACTH/cortisol release, it has been used as a provocative test to evaluate pituitary reserve in suspected deficiency states. Several case reports illustrate its role in uncovering isolated ACTH deficiency Tomohide 2025 and combined GH/ACTH deficiency Kazuki 2021. In one case, a patient with refractory hypoglycemia was found to have pituitary-origin disease partly characterized using GHRP-2 testing Arkadeep 2021. This dual stimulation profile — often considered a liability in therapeutic use — becomes clinically useful in the diagnostic context.
How it's used
In studies and self-reported protocols, doses range from 100 mcg to 300 mcg per injection, administered subcutaneously (injected under the skin). Intranasal administration has also been reported, though bioavailability via that route is lower and less consistent. Injection frequency is typically two to three times daily, with timing structured around meals (pre-meal to leverage appetite effects) and a dose at bedtime to align with the natural nocturnal GH pulse. The half-life is approximately 55 minutes, so effects are short-lived and pulse-dependent. The diagnostic dose used in clinical GH stimulation tests is typically 100 mcg administered intravenously or subcutaneously as a single dose under medical supervision Sawako 2022 Takanori 2024.
Side effects and safety
The most clinically significant side effects are cortisol and prolactin elevation — these are dose-dependent and consistent across studies, not rare reactions Tomohide 2025. Chronically elevated cortisol can impair sleep quality, increase fat deposition (particularly visceral), suppress immune function, and worsen insulin sensitivity. Chronically elevated prolactin can cause gynecomastia (breast tissue development in men), reduced libido, and suppressed testosterone. Water retention, flushing, mild headache, and increased appetite are commonly reported in self-use contexts. The appetite effect is real and should be anticipated. Like all GH secretagogues, GHRP-2 is contraindicated in active malignancy because GH and IGF-1 (insulin-like growth factor 1, the downstream mediator of GH's anabolic effects) can accelerate tumor growth. Diabetes and pre-diabetes are relative contraindications given cortisol's glucose-raising effects compounding on top of GH-induced insulin resistance. Long-term safety data in healthy adults using GHRP-2 therapeutically does not exist — all chronic-use risk assessment is extrapolated from GH physiology and short-term studies.
Bottom line
GHRP-2 is a well-characterized GH secretagogue with legitimate diagnostic uses and real anabolic potential, but its cortisol and prolactin side effects make it harder to use cleanly than ipamorelin for the same goals. The diagnostic evidence base is solid; the therapeutic evidence base in healthy adults is thin. People who are cortisol-sensitive, metabolically compromised, or concerned about prolactin-related effects have better options.